Efficacy and Safety of Selective Aldosterone Synthase Inhibitors in Uncontrolled Hypertension: A Systematic Review and Dose-Specific Network Meta-Analysis of Randomized Controlled Trials.
Jul 2026· Cardiology in Review· 1 citation· 52 references
Medicine
Abstract
Selective aldosterone synthase inhibitors (ASIs), including baxdrostat and lorundrostat, target CYP11B2 while sparing cortisol synthesis, offering a novel strategy for resistant and uncontrolled hypertension. Yet existing meta-analyses have included nonselective agents or omitted the latest phase 3 data. We searched PubMed, Scopus, Cochrane, and Web of Science from inception to March 7, 2026, for randomized controlled trials of selective ASIs versus placebo. Random-effects dose-level network meta-analyses were performed for 16 efficacy and safety outcomes. Trial sequential analysis assessed evidence firmness, and certainty was rated using the GRADE CINeMA framework. Six randomized controlled trials (2856 patients across 30 countries) were included. ASIs reduced office systolic blood pressure versus placebo [mean difference (MD) -8.22 mm Hg; 95% CI, -9.43 to -7.00; I2 = 0%]. Baxdrostat 2 mg achieved the greatest reductions in office systolic blood pressure (-10.24 mm Hg), office diastolic blood pressure (-4.40 mm Hg), and ambulatory systolic blood pressure (-14.53 mm Hg). ASIs lowered serum aldosterone and raised plasma renin activity. Safety signals included reduced eGFR (MD -6.91 mL/min/1.73 m2), hyperkalemia [risk ratio (RR) 5.04], hyponatremia (RR 2.11), and symptomatic hypotension (RR 3.17), with dose-dependent risks most pronounced for lorundrostat 100 mg.
Baxdrostat 1 mg and 2 mg significantly increased overall adverse events and hyperkalemia, whereas serious adverse events were not significantly increased, and both higher doses significantly increased hyperkalemia risk.
M. Shahzaib, Hafsa Ali, Muhammad Roshaan et al.· Naunyn-Schmiedeberg's Archiv...· 0 citations
Findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonis...
Muhammad Burhan, Z. Shahid, M. Naveed et al.· The Annals of Pharmacotherap...· 0 citations
Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, the...
G. Marino, S. D. Di Fusco, E. Graziano et al.· Journal of Clinical Medicine· 0 citations
The aldosterone‐related sodium‐retention pathway as an important therapeutic target in RH is supported, and newer ASIs and amiloride may represent pathway‐based alternatives for selected patients.
Yi-Liang Tsou, Yu-Hong Wang, Yi-Siou Lin et al.· The Journal of Clinical Hype...· 0 citations
BACKGROUND AND AIMS
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and kidney outcomes, but their effects on circulating inflammatory biomarkers remain uncertain. We systematically reviewed randomized evidence on the effects of SGLT2is on peripheral-blood inflammatory biomarkers.
METHODS
P...
Mehmet Kanbay, Ermeena Shah, Rama Al-Shiab et al.· Diabetes, obesity and metabo...· 0 citations
Overall, zilebesiran produced significant and consistent BP reductions, especially in ambulatory measures, with a favorable safety profile, and builds on previous meta-analyses that included only 2 RCTs; this updated analysis reflects the need for novel therapeutic options.
Muhammad Hussain, Muhammad Hassan, Asharib Sohaib et al.· European Journal of Clinical...· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.